Accelerating global chemical product innovation and development

Scientific and regulatory support to market and sustain your products in any jurisdiction.

Competitive Advantage

Acta is a global scientific and regulatory consulting firm that assists companies that make and use chemicals with strategic commercialization planning and complex product registration and compliance matters.

We partner with our clients to help them get products quickly and efficiently to market — in any country or locale — and keep them there when challenged by a new regulatory regime, issue, or set of rules.

More About Us

Knowledge & Insights

  December 17, 2024
Memoranda
PFAS – What to Know Now, and What to Expect

Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are attracting global legal, regulatory, commercial, and litigation attention as no other...

  March 24, 2025
Memoranda
Canada Releases Final State of PFAS Report and Proposed Risk Management Approach

On March 5, 2025, Environment and Climate Change Canada (ECCC) announced the availability of its final State of Per- and Polyfluoroalkyl Substances...

  March 21, 2025
Memoranda
EPA Releases New TSCA and FIFRA Enforcement Policies

On January 17, 2025, days before the end of President Biden’s term, the U.S. Environmental Protection Agency (EPA) released two new enforcement...

  March 14, 2025
Global Regulatory Updates
Global Regulatory Update for March 2025

ABA And B&C Announce Release Of “Chemical Product Law and Supply Chain Stewardship” Book: The Acta Group (Acta®) and Bergeson & Campbell,...

  January 28, 2025
Memoranda
EPA Releases Draft Scope Document for Vinyl Chloride TSCA Risk Evaluation

On January 16, 2025, the U.S. Environmental Protection Agency (EPA) announced the availability of and requested public comment on the draft scope of...

  January 27, 2025
Memoranda
EPA Proposes Risk Management Rule to Protect Workers from Inhalation Exposure to PV29

On January 14, 2025, the U.S. Environmental Protection Agency (EPA) issued a proposed rule to address the unreasonable risk of injury to human health...

  January 17, 2025
Memoranda
EPA Releases Final Risk Evaluation for DINP, Finding Unreasonable Risk of Injury to Human Health When Workers Are Exposed under Four COUs

On January 14, 2025, the U.S. Environmental Protection Agency (EPA) released the final risk evaluation for diisononyl phthalate (DINP) conducted under...

Seminars & Webinars

  March 4, 2025
Seminars & Webinars
Society of Quality Assurance Annual Meeting, April 6-11, 2025, Orlando, FL

The 41st SQA Annual Meeting will cover “hot topics” in GCP, GLP, GMP, pharmacovigilance, scientific archiving, computer validation,...

  March 14, 2025
Seminars & Webinars
GlobalChem, April 14-16, 2025, Washington, D.C.

GlobalChem, presented by the American Chemistry Council, brings together industry professionals to review recent developments in global chemicals...

  March 14, 2025
Seminars & Webinars
PFAS Updates: What’s Happening in the U.S. and EU, May 13, 2025, 11:00 a.m. – 12:00 p.m. (EDT), via webinar

B&C and Acta are pleased to present “PFAS Updates: What’s Happening in the U.S. and EU.” More details will be posted closer to the webinar....

With offices in the U.S., UK, and Europe, and partners and agents in China, South Korea, Turkey, Mexico, and more, Acta offers expertise with regulatory programs and chemical product approvals in North America, Europe, South and Central America, and Asia.

Our Firms

our people

Experienced industry and agency scientists, including organic chemists, toxicologists, exposure experts, five Ph.D.’s. Government affairs and regulatory specialists including three high-level EPA alumni. Business strategists with decades of experience directing worldwide regulatory compliance.

Acta consultants manage products from concept to approval, delivering skills and experience with specific product areas in government and industry.

Our three affiliated firms -- B&C, Acta, and BCCM -- provide a full range of global support for the commercialization of chemicals, biocides, and products of industrial biotechnology, nanotechnology, and synthetic biology.